

# Lawrence Berkeley National Laboratory

## LBL Publications

### Title

Generation of Pseudomonas putida KT2440 Strains with Efficient Utilization of Xylose and Galactose via Adaptive Laboratory Evolution

### Permalink

<https://escholarship.org/uc/item/5tf7f65t>

### Journal

ACS Sustainable Chemistry & Engineering, 9(34)

### ISSN

2168-0485

### Authors

Lim, Hyun Gyu  
Eng, Thomas  
Banerjee, Deepanwita  
[et al.](#)

### Publication Date

2021-08-30

### DOI

10.1021/acssuschemeng.1c03765

Peer reviewed

# Generation of *Pseudomonas putida* KT2440 Strains with Efficient

## Utilization of Xylose and Galactose via Adaptive Laboratory Evolution

Hyun Gyu Lim<sup>†,§</sup>, Thomas Eng<sup>†,§</sup>, Deepanwita Banerjee<sup>†,§</sup>, Geovanni Alarcon<sup>a</sup>, Andrew K. Lau<sup>†,§</sup>,  
Mee-Rye Park<sup>†,§</sup>, Blake A. Simmons<sup>†,§</sup>, Bernhard O. Palsson<sup>†,\*,||,#</sup>, Steven W. Singer<sup>†,§</sup>, Aindrila  
Mukhopadhyay<sup>†,§,††</sup>, Adam M. Feist<sup>†,\*,||,\*</sup>

<sup>†</sup>Department of Bioengineering, University of California San Diego, 9500 Gilman Dr., La Jolla,  
CA 92093, USA

<sup>‡</sup>Joint BioEnergy Institute, 5885 Hollis street, 4th floor, Emeryville, CA 94608, USA

<sup>§</sup>Biological Systems and Engineering Division, Lawrence Berkeley National Laboratory, 1  
Cyclotron Road, Berkeley, CA 94702, USA

<sup>||</sup>Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, 2800  
Kgs, Lyngby, Denmark

<sup>#</sup>Department of Pediatrics, University of California, San Diego, CA 92093, USA

<sup>††</sup>Environmental Genomics and Systems Biology Division, Lawrence Berkeley National  
Laboratory, 1 Cyclotron Road, Berkeley, CA 94702, USA

\*To whom correspondence should be addressed.

(Adam M. Feist)

[afeist@ucsd.edu](mailto:afeist@ucsd.edu)

## 22 Abstract

23 While *Pseudomonas putida* KT2440 has great potential for biomass-converting processes,  
24 its inability to utilize the biomass abundant sugars xylose and galactose has limited its applications.  
25 In this study, we utilized Adaptive Laboratory Evolution (ALE) to optimize engineered KT2440  
26 with heterologous expression of *xylD* encoding xylonate dehydratase from *Caulobacter crescentus*  
27 and *galETKM* encoding UDP-glucose 4-epimerase, galactose-1-phosphate uridylyltransferase,  
28 galactokinase, and galactose-1-epimerase from *Escherichia coli* K-12 MG1655. Poor starting  
29 strains growth ( $<0.1 \text{ h}^{-1}$  or none) was evolutionarily optimized to rates of up to  $0.25 \text{ h}^{-1}$  on xylose  
30 and  $0.52 \text{ h}^{-1}$  on galactose. Whole-genome sequencing, transcriptomic analysis, and growth screens  
31 revealed significant roles of *kguT* encoding a 2-ketogluconate operon repressor and 2-  
32 ketogluconate transporter, and *gtsABCD* encoding an ATP-binding cassette (ABC) sugar  
33 transporting system in xylose and galactose growth conditions, respectively. Finally, we expressed  
34 the heterologous indigoidine production pathway in the evolved and unevolved engineered strains  
35 and successfully produced 3.2 g/L and 2.2 g/L from 10 g/L of either xylose or galactose in the  
36 evolved strains whereas the unevolved strains did not produce any detectable product. Thus, the  
37 generated KT2440 strains have the potential for broad application as optimized platform chassis  
38 to develop efficient microorganism-based biomass-utilizing bioprocesses.

39  
40 Keywords: Adaptive laboratory evolution, *Pseudomonas putida*, xylose, galactose, Weimberg  
41 pathway, Leloir pathway

42

## 1. Introduction

*Pseudomonas putida* KT2440 (hereafter, KT2440) has been widely studied for its utilization as a microbial platform in biorefinery processes due to its tolerance to various stresses and the ability to grow on biomass-derived aromatics (e.g., coumaric acid).<sup>1-3</sup> Because conventional microbial hosts such as *Escherichia coli* are incapable of utilizing such aromatics, the use of KT2440 is expected to improve the cost effectiveness of bioprocesses by achieving whole-conversion of biomass-derivable carbon sources. In this regard, so far, several studies have been conducted to produce various biochemicals using KT2440.<sup>1</sup>

Despite these great advantages, one drawback in the use of KT2440 is that it cannot metabolize certain sugars (e.g., xylose, galactose) obtainable from biomass.<sup>4,5</sup> To enable xylose and galactose utilization, KT2440 has previously been engineered by the heterologous introduction of key missing genes in known sugar utilization pathways (Figure S1 and Table S1). Specifically, the xylose isomerase pathway has been constructed by the expression of xylose isomerase (XylA) and xylulokinase (XylB) from *E. coli*.<sup>6-9</sup> Additionally, the Weimberg pathway (i.e., xylose oxidative pathway) has been constructed by the expression of xylonate dehydratase (XylD) from *Caulobacter crescentus*.<sup>10-12</sup> Enabling galactose utilization has been less studied compared to xylose metabolism. Two studies reported the construction of the De Ley–Doudoroff (DLD) pathway (i.e., galactose oxidative pathway)<sup>13</sup> or Leloir pathway<sup>14</sup> by the expression of DgoKAD, galactonate catabolic enzymes, from *P. fluorescens* SBW2 or GalETKM, galactose operon, from *E. coli* K-12 MG1655, respectively.

While it was shown that KT2440 can be engineered to utilize xylose and galactose, several limitations remain. We currently have an insufficient understanding of which endogenous genes are involved in the sugar catabolism. Furthermore, initial studies have expressed heterologous

1  
2  
3 66 genes using plasmids, which is not ideal nor preferable for industry-scale cultivations, as plasmid-  
4  
5 67 based expression increases genotypic or phenotypic instability due to its heterogeneous nature.<sup>15,16</sup>  
6  
7  
8 68 However, genome-based engineering often resulted in unsatisfactory cell growth (i.e., slow growth  
9  
10 69 rate or long lag phase) which makes their practical deployment challenging. The successful  
11  
12 70 activation of non-native sugar utilization pathways with chromosomal expression has been  
13  
14 71 demonstrated for only the xylose isomerase pathway<sup>16</sup> and the De Ley-Doudoroff pathway.<sup>13</sup> Since  
15  
16 72 each utilization pathway generates different intermediates and biochemical yields,<sup>10</sup> further studies  
17  
18  
19 73 to construct less-explored pathways in KT2440 are warranted.

20  
21  
22 74 In recent decades, the approach of adaptive laboratory evolution (ALE) has shown  
23  
24 75 significant potential to generate useful strains for industry-relevant purposes.<sup>17</sup> The continuous cell  
25  
26 76 culture and growth-based selection allow for the accumulation of beneficial mutations for  
27  
28 77 improved fitness under a given condition. The recent development of automated ALE  
29  
30 78 platforms<sup>18,19</sup> enabled multiplexity and controllability to change environments dynamically (e.g.,  
31  
32  
33 79 substrate feeding). In addition to the strain generation, the increased accessibility to the next-  
34  
35 80 generation sequencing allows for the rapid identification of genomic and transcriptomic variations  
36  
37  
38 81 in evolved cells, providing hints to understand mutational mechanisms. Indeed, many strains with  
39  
40 82 industry-relevant phenotypes (e.g., higher tolerance, substrate utilization)<sup>20-26</sup> have been generated  
41  
42 83 and their mutational mechanisms were also suggested or validated through reverse engineering. In  
43  
44 84 this regard, it was expected that the ALE approach and related analysis has the potential to generate  
45  
46 85 strains with improved sugar utilization and that the resulting mutational mechanisms could lead to  
47  
48  
49 86 a deeper understanding of how strains can optimize novel phenotypes related to the introduction  
50  
51 87 of heterologous pathways.

52  
53  
54 88

1  
2  
3 89 In this study, an adaptive laboratory evolution (ALE) approach was applied to engineered  
4  
5 90 KT2440 strains for the efficient utilization of two biomass-abundant sugars, xylose and galactose.  
6  
7 91 Initially, we obtained engineered KT2440 strains (*P. putida xylD* and *P. putida galETKM*,  
8  
9  
10 92 Supplementary Data 1) in which *xylD* from *C. crescentus* or *galETKM* from *E. coli* was integrated  
11  
12 93 into the chromosome to construct the Weimberg pathway for xylose utilization or the Leloir  
13  
14 94 pathway for galactose utilization. Then, we evolved the strains in minimal media supplemented  
15  
16 95 with xylose or galactose and we successfully obtained evolved clones that grew on xylose or  
17  
18 96 galactose with higher growth rates (0.25 h<sup>-1</sup> on xylose or 0.52 h<sup>-1</sup> on galactose). Whole-genome  
19  
20 97 and transcriptome sequencing, growth characterization of evolved isolates revealed key  
21  
22 98 mechanisms that improved sugar utilization. We confirmed their capability to serve as a platform  
23  
24 99 by demonstrating their efficient production of indigoidine, a naturally-found blue pigment.<sup>27</sup>  
25  
26  
27  
28 100 Collectively, we expect that the generated strains and related mutational mechanisms will be  
29  
30 101 greatly useful for developing KT2440-based microbial processes for the efficient production of  
31  
32 102 various biochemicals from biomass.

## 33 34 35 36 103 **2. Materials and Methods**

### 37 38 39 104 **Bacterial cells, plasmids, and reagents**

40  
41  
42 105 Strains and plasmids used in this study are listed in Table S2 and S3. Plasmids were  
43  
44 106 constructed by using a NEBuilder HiFi DNA assembly kit from New England Biolabs (NEB,  
45  
46 107 Ipswich, MA, USA). Oligonucleotides, synthesized by Integrated DNA Technologies (IDT,  
47  
48 108 Coralville, IA, USA), are listed in Table S4. The *xylD* gene was synthesized by IDT and its 5'  
49  
50 109 synthetic UTR was designed by using UTR Designer.<sup>28</sup> For DNA amplification, Q5 High-Fidelity  
51  
52 110 DNA polymerase or OneTaq DNA polymerase (NEB) was used. Plasmids were purified by using  
53  
54 111 a ZymoPURE Plasmid Miniprep kit from Zymo Research (Irvine, CA, USA). Scar-less genome

1  
2  
3 112 engineering of the KT2440 strain was conducted as described in a previous study<sup>22</sup>. All chemicals  
4  
5 113 were purchased from Sigma Aldrich (St. Louis, MO, USA).  
6  
7

## 8 9 114 **Cell cultures**

10  
11 115 Cell cultures were conducted in an Luria-Bertani (LB, 10 g/L tryptone, 5 g/L yeast extract,  
12  
13 116 10 g/L NaCl) or phosphate-buffered minimal medium<sup>22</sup> at 30 °C. Flask-scale cell cultures were  
14  
15 117 performed with a 30 mL cylindrical tube containing 15 mL of a medium. Seed cultures were  
16  
17 118 prepared by inoculating colonies from LB agar plates into the minimal medium supplemented with  
18  
19 119 4 g/L glucose. Grown cultures were diluted into the fresh medium at the optical density at 600 nm  
20  
21 120 ( $OD_{600}$ ) of 0.1. When  $OD_{600}$  reached 0.6-1, cells were harvested and re-inoculated into xylose or  
22  
23 121 galactose supplemented minimal media at  $OD_{600}$  of 0.05 to initiate main cultures. Cultures were  
24  
25 122 continuously stirred at 1,100 rpm.  $OD_{600}$  was measured using a Biomate 3S bench-top  
26  
27 123 spectrophotometer from Thermo Fisher Scientific (Waltham, MA, USA). For ALE, 150  $\mu$ L of  
28  
29 124 cultures at the late-exponential phase ( $OD_{600}$  of 0.6-1) were passaged in an automated platform.<sup>18</sup>  
30  
31 125 During a weaning phase, 1 g/L of glucose was additionally supplemented, but its concentration  
32  
33 126 was changed depending on biomass formation.<sup>24</sup> For a small-scale cultivation, cells were grown  
34  
35 127 on a microtiter plate with a culture volume of 200  $\mu$ L using an M200 Infinite Pro microplate reader  
36  
37 128 from Tecan (Männedorf, Switzerland).  
38  
39  
40  
41  
42

43 129 For the indigoidine production, cells were cultured in 250 mL baffled flasks containing 60  
44  
45 130 mL of a modified minimal medium where 2 g/L of  $(NH_4)_2SO_4$  was substituted with 100 mM  $NH_4Cl$   
46  
47 131 and the sugar concentrations were increased to 10 g/L. The flasks were shaken at 200 rpm and 30  
48  
49 132 °C. Arabinose is not catabolized by KT2440 and thus 3 g/L was included to induce the expression  
50  
51 133 of the indigoidine synthetic genes<sup>14</sup> at 0 h.  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 134 **Genome and transcriptome sequencing**

135 Genomic DNA samples were prepared by using a Quick-DNA Fungal/Bacterial Miniprep  
136 kit from Zymo Research. Sequencing library samples were prepared by using a Nextera XT kit  
137 from illumina (San Diego, CA, USA). Raw sequencing reads were obtained by using a NovaSeq  
138 6000 (illumina) at the UC San Diego IGM Genomics Center and analyzed by using Breseq (version  
139 0.33.1)<sup>29</sup> and Bowtie2 (version 2.3.4.1).<sup>30</sup> Analysis results were uploaded to ALEdb v1.0.<sup>31</sup>

140 RNA samples were prepared from cells at the exponential phase ( $OD_{600}$  0.4-0.6) using an  
141 RNAprotect Bacteria Reagent from Qiagen and a Quick-RNA Fungal/Bacterial Miniprep kit from  
142 Zymo Research. Ribosomal RNA was removed as described in a previous study.<sup>22</sup> Paired-end  
143 libraries were prepared by using a KAPA RNA HyperPrep kit from Kapa Biosystems (Wilmington,  
144 MA, USA) and sequenced using the NovaSeq 6000. Raw sequencing files were processed using  
145 Bowtie2<sup>30</sup> and summarizeOverlaps.<sup>32</sup> Differentially expressed genes were detected by using  
146 DEseq2.<sup>33</sup>

## 147 **Biomass and metabolite quantification**

148 Cell biomass was determined by converting  $OD_{600}$  to a dry cell weight (DCW)/L using a  
149 conversion factor of 0.38.<sup>8</sup> Metabolite concentrations were quantified by using a 1260 Infinity II  
150 LC system (Agilent, Santa Clara, CA, USA) equipped with an HPX-87H (Biorad, Hercules, CA,  
151 USA) and a refractive index detector. 5 mM  $H_2SO_4$  was used as a mobile phase at a flow rate of  
152 0.5 mL/min. The column temperature was maintained at 45 °C.

153 Indigoidine was quantified after its extraction using dimethyl sulfoxide as described in a  
154 previous study.<sup>14,34</sup> The absorbance at 612 nm was measured by using a microtiter plate reader  
155 from BD Biosciences (Molecular Devices, CA, USA). The theoretical maximum yield from xylose  
156 was calculated as 0.74 g indigoidine/g xylose using the modified KT2440 metabolic model



1  
2  
3 157 iJN1462<sup>3</sup> to account for xylose utilization through the Weimberg pathway. The yield from  
4  
5 158 galactose (0.77 g indigoidine/g galactose) was adapted from a previous study.<sup>14</sup>  
6  
7

8 159

### 9 10 160 **Protein structure prediction and visualization**

11  
12 161 Protein structures were predicted by using the I-TASSER software<sup>35</sup>. Predicted structures  
13  
14  
15 162 were visualized by using the UCSF Chimera.<sup>36</sup>  
16  
17

18 163

19 164

## 20 21 165 **3. Results**

### 22 23 24 166 **Adaptive laboratory evolution of engineered *P. putida* strains for xylose and galactose** 25 26 27 167 **utilization enhances catalytic capabilities**

28  
29 168 The initial growth characteristics of two engineered KT2440 strains (*P. putida xylD* and *P.*  
30  
31 169 *putida galETKM*) in minimal media supplemented with either xylose or galactose as a sole carbon  
32  
33  
34 170 source were characterized. In the *P. putida xylD* strain, only the *xylD* gene from *C. crescentus* was  
35  
36 171 introduced to construct the Weimberg pathway for xylose utilization because it was shown that the  
37  
38 172 conversion of xylose to xylonate can be mediated by the native glucose dehydrogenase (encoded  
39  
40 173 by *gcd*, PP\_1444) (Figure S1).<sup>11</sup> *xylD* was expressed from the chromosome under a constitutive  
41  
42 174 promoter and 5'-untranslated region (Supplementary Note 1). Consistent with previous  
43  
44 175 observations,<sup>11</sup> the expression of *xylD* enabled growth of the strain on xylose as a sole carbon  
45  
46 176 source (Figure S2A); however, it showed a relatively low growth rate ( $\mu$ ,  $\sim 0.07 \text{ h}^{-1}$ ), long lag time  
47  
48 177 ( $> 36 \text{ h}$ ), and clumping (data not shown) during initial growth characterizations. For the second  
49  
50 178 starting strain, we utilized a previously constructed *P. putida galETKM* strain<sup>14</sup>, in which the  
51  
52 179 native galactose operon (*galETKM*) of *E. coli* K-12 MG1655 was introduced into the chromosome  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 180 to construct the Leloir pathway. This *P. putida galETKM* starting strain did not display observable  
4  
5 181 growth on galactose minimal medium during a 48 h culture screen (Figure S2B); the strain did  
6  
7 182 grow under a rich medium or glucose minimal medium condition. These initial screens set the  
8  
9  
10 183 starting parameters for a multifaceted ALE strategy to improve the sugar utilization of both  
11  
12 184 KT2440 strains on their respective sole carbon source sugars.

13  
14  
15 185 ALE experiments with two different strategies were conducted to optimize growth rates  
16  
17 186 and catalytic activity on the targeted xylose and galactose sugars. Given that the *P. putida xylD*  
18  
19 187 strain could initially grow on xylose, we continuously propagated the strain in a constant condition  
20  
21 188 ALE on an automated platform<sup>37</sup> on minimal medium supplemented with xylose (4 g/L) as the  
22  
23 189 sole carbon source (Figure 1A). For the *P. putida galETKM* starting strain, which could not  
24  
25 190 initially grow solely on galactose within 48 h, we propagated the strain in a minimal medium  
26  
27 191 containing 4 g/L galactose and the additional supplement of 1 g/L glucose to support cell growth  
28  
29 192 and subsequent mutation accumulation (Figure 1B); this complementary approach was also  
30  
31 193 automated and adapted from Guzman et al<sup>24</sup>. The supplemented culture (hereafter referred to as  
32  
33 194 the main culture) was regularly screened by inoculating it into a fresh galactose-only minimal  
34  
35 195 medium (hereafter referred to as the test culture). If cells failed to produce an observable grow rate  
36  
37 196 during 48 h in the test culture, it was discarded, and the main culture was continued. Once a stable  
38  
39 197 growth rate ( $\mu > 0.05 \text{ h}^{-1}$ ) in a test culture was observed for a given replicate after several  
40  
41 198 generations, this culture was continued as a constant condition galactose-only culture and  
42  
43 199 continued for growth rate selection until the end of the experiments. It should be noted that in the  
44  
45 200 original main culture line, the amount of glucose was gradually decreased, depending on the final  
46  
47 201 biomass density during stationary phase, as previously described.<sup>24</sup> Both strategies of automated  
48  
49 202 ALE experiments were parallelly conducted with four independent biological replicates (Table S5).  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 203 The ALE experiments were conducted for approximately three months (203-479  
4  
5 204 generations, equivalent to  $11.5\text{-}30.5 \times 10^{11}$  cumulative cell divisions). Notably, the growth rates  
6  
7 205 of all independent replicates of *P. putida xylD* populations were significantly increased at an early  
8  
9 206 stage of the experiments (ALE1-4 and Figure 1C). However, no further significant increases were  
10  
11 207 observed; the final growth rates of populations were between  $0.22$  and  $0.25 \text{ h}^{-1}$ . In the case of the  
12  
13 208 *P. putida galETKM* strain (Figure 1D), successful growth on solely galactose was observed in  
14  
15 209 three replicates (ALE5, ALE6, and ALE8). The passage numbers before displaying the stable  
16  
17 210 growth varied between 35 – 44 flasks (Table S5). Although the initial growth rates of these novel  
18  
19 211 populations were relatively low (approximately  $0.1 \text{ h}^{-1}$ ), the rates were gradually increased over  
20  
21 212 time and reached between  $0.33 \text{ h}^{-1}$  and  $0.52 \text{ h}^{-1}$ , indicating that the evolved strains acquired  
22  
23 213 beneficial mutations which improved galactose catabolism.

24  
25  
26  
27 214 Clones were isolated from each experiment at several time points and validated to display  
28  
29 215 the observed phenotypes from the evolved populations. Two or three intermediate evolutionary  
30  
31 216 time points for ALE 1 - 4 and four points for ALE 5, 6, 8 (Figure 1C and 1D) were isolated and  
32  
33 217 their specific growth rates during exponential growth were measured in the xylose or galactose  
34  
35 218 minimal medium, respectively (Figure 1E and 1F). For clones derived from the *xylD* starting strain,  
36  
37 219 the growth rates of isolates generally corresponded to the growth rates of populations from which  
38  
39 220 the strains were isolated; they were in a range of  $0.20 \text{ h}^{-1}$  -  $0.26 \text{ h}^{-1}$ , regardless of isolation  
40  
41 221 timepoints. Conversely, the growth rates of evolved *P. putida galETKM* clones from later  
42  
43 222 evolutionary time populations were greater than those isolated from early populations; the end-  
44  
45 223 point isolates showed the growth rates between  $0.35 \text{ h}^{-1}$  and  $0.52 \text{ h}^{-1}$ .

46  
47 224 Growth, sugar consumption, and biomass yields were determined in detail to  
48  
49 225 physiologically characterize evolved strains and compare them to the starting strains (Figure 2).  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 226 The earliest isolated *P. putida xylD* clones (A1\_F11\_I1, A2\_F10\_I1, A3\_F14\_I1, and A4\_F11\_I1)  
4  
5 227 from first-time points and the end-point *P. putida galETKM* clones (A5\_F85\_I1, A6\_F90\_I1, and  
6  
7 228 A8\_F92\_I1) were selected as representative clones for in depth physiological characterization.  
9  
10 229 While the starting strains showed no growth with the consumption of a negligible or small amount  
11  
12 230 of xylose or galactose, the evolved strain demonstrated greatly improved growth and sugar  
13  
14 231 consumption. The four evolved *P. putida xylD* clones showed similar growth and sugar  
15  
16 232 consumption profiles (Figure 2A and 2B). Among them, their xylose uptake rates varied by 1.6-  
17  
18 233 fold (Figure 2A-C); the A1\_F11\_I1 strain showed the highest uptake catalytic rate (1.2 g xylose g  
19  
20 234 DCW<sup>-1</sup> h<sup>-1</sup>), but the lowest biomass yield (0.20 g xylose g DCW<sup>-1</sup>). Interestingly, the three isolated  
21  
22 235 evolved *P. putida galETKM* clones showed noticeably different growth and sugar consumption  
23  
24 236 profiles (Figure 2D-F). Only the A6\_F90\_I1 strain fully grew and consumed the provided 4 g/L  
25  
26 237 galactose in 24 h of culturing at the lowest uptake rate of 1.3 g galactose g DCW<sup>-1</sup> h<sup>-1</sup> of all isolated  
27  
28 238 clones. While the sugar uptake rates of the other *P. putida galETKM* clones were 1.3- and 2.0-fold  
29  
30 239 higher, these two strains did not fully consume galactose and growth ceased after reaching OD<sub>600</sub>  
31  
32 240 of 0.85 or 1.2, resulting in two- or three-times less final biomass density and yield. Additionally,  
33  
34 241 the growth rates of all the characterized clones on glucose remained at similar levels compared to  
35  
36 242 the wild-type strain (Figure S3). While there are several differences, all isolates showed  
37  
38 243 significantly improved sugar (i.e., xylose and galactose) consumption capabilities when compared  
39  
40 244 to the starting strains, confirming that the ALE strategy was successful in generating strains with  
41  
42 245 enhanced catalytic activity for both xylose and galactose utilization.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 247 **Genomic and transcriptomic sequencing elucidates causal mutations and their impact on**  
4  
5 248 **enhanced catalytic phenotypes**  
6

7  
8 249 To identify beneficial mutations in the engineered and evolved strains on xylose and  
9  
10 250 galactose, we conducted whole-genome sequencing of clones isolated during the middle (i.e.,  
11  
12 251 intermediate) and end of the evolutions (i.e., endpoints). Furthermore, the transcriptomes of a set  
13  
14 252 of selected clones were measured and analyzed to understand the effect of mutations and resulting  
15  
16 253 transcriptional changes in the different carbon source culturing environments.  
17  
18

19 254 *3.2.1. Whole-genome sequencing revealed mutations on transport and catabolic processes*  
20

21 255 Whole genome sequencing of eleven *P. putida xylD* and twelve *P. putida galETKM*  
22  
23 256 evolved isolates successfully revealed several genes or regions (hereafter, collectively referred to  
24  
25 257 as regions) commonly mutated across the independently evolved replicates (Supplementary  
26  
27 258 Information, Figure 3A and 3B). Surprisingly, mutations in six (*ptxS*, *kguT*, *gacS*, *ftsH*, PP\_4173,  
28  
29 259 and *galP-I/PP\_1174*) and three (*gtsABCD*, *oprB-I/yeaD*, and *oprB-II*) regions accounted for 44%  
30  
31 260 (38 out of 86) and 32% (20 out of 63) of the total mutations in *P. putida xylD* and *P. putida*  
32  
33 261 *galETKM* isolates, respectively (Table 1). Although we expected frequent mutations in the  
34  
35 262 heterologous genes, given that heterologous gene expression cassettes have been mutation targets  
36  
37 263 in previous heterologous pathway optimization studies,<sup>16,38</sup> only the *galETKM* region was mutated  
38  
39 264 in isolates from ALE 8 where a single amino acid change mutation in *galK* and single nucleotide  
40  
41 265 change in the intergenic region between *galE* and its neighboring gene, *prfC* were observed; no  
42  
43 266 mutations occurred in the *xylD* region. Furthermore, it should be noted that the A4\_F56\_I1 and  
44  
45 267 A6\_F90\_I1 clones acquired mutations in *mutS*, encoding a mismatched DNA repair protein.<sup>39</sup> In  
46  
47 268 particular, a relatively higher number of mutations (42 mutations) were identified in the former  
48  
49 269 strain when compared to mutation numbers of other isolates (up to 10 mutations).  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 270 The two genes responsible for one of three peripheral glucose utilization pathways (*ptxS*  
4  
5 271 and *kguT*, Figure 3C), were highly mutated in all eleven sequenced *P. putida xylD* isolates (100%  
6  
7 272 for *ptxS* and 82% for *kguT*) suggesting their critical roles for the improved xylose utilization  
8  
9 273 (Figure 3A). It is known that *ptxS* encodes a LacI-family transcription factor, namely a 2-  
10  
11 274 ketogluconate utilization repressor. The binding of 2-ketogluconate mediates the dissociation of  
12  
13 275 PtxS from the promoter region of the *kguEKT-ptxD* operon.<sup>40-42</sup> Since the mutations which altered  
14  
15 276 the DNA binding motif (R30S, S29F, or V28F) and partial deletions ( $\Delta 51$  or  $\Delta 438$  bp) of PtxS  
16  
17 277 were identified in the isolates, it implies that these mutations de-repressed the expression of *kguE*,  
18  
19 278 *kguK*, *kguT*, and *ptxD* and as a result, enabled an increase in xylose catabolism. Mutations found  
20  
21 279 in KguT were mostly SNPs (seven unique SNPs found overall) which effected changes in single  
22  
23 280 amino acids, a small deletion, or changes in a few amino acids at the end of the protein (Figure  
24  
25 281 S4A), likely effecting the transportation of xylonate. Interestingly, it was found that the  
26  
27 282 A2\_F10\_I1 and A3\_F14\_I1 strains with relatively lower xylose uptake rates (Figure 2C) did not  
28  
29 283 acquire any mutations in KguT. Thus, an association can be drawn between major xylose catabolic  
30  
31 284 and growth rate improvements and mutations in *ptxS* and *kguT* simultaneously in the strains  
32  
33 285 examined.

34  
35 286 Additional genetic regions were independently mutated in two or more *xylD* ALE  
36  
37 287 experiments (Table 1), in addition to the *ptxS* and *kguT* regions, at a lower frequency. These  
38  
39 288 regions were *gacS* (36%), *ftsH* (27%), PP\_4173 (27%), and *galP-I/PP\_1174* (the intergenic region  
40  
41 289 between *galP-1* and PP\_1174, 18%). Mutations in *gacS* (encoding a sensor protein, GacS) and  
42  
43 290 PP\_4173 (encoding a two-component system sensor histidine kinase/response regulator) were also  
44  
45 291 found in previous ALE studies examining tolerance to different compounds, but with a similar  
46  
47 292 base media and growth environment.<sup>21,22</sup> Thus, the *gacS* and PP\_4173 mutations appear to be  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 293 related to general adaptation to the media or culturing environment used in this study. However,  
4  
5 294 the mutations in *ftsH* (encoding an Integral membrane ATP-dependent zinc metallopeptidase) and  
6  
7 295 *galP-I* (encoding a porin-like protein)/PP\_1174 (encoding a hypothetical protein) have not been  
8  
9  
10 296 previously identified in an ALE study and it is unclear how they relate to the specific xylose  
11  
12 297 utilization phenotype.

13  
14 298 In the case of evolved *P. putida galETKM* isolates, the three commonly mutated regions  
15  
16 299 were related to the transport of glucose (Table 1), implying galactose transportation was the major  
17  
18 300 bottleneck. Most importantly, mutations in the *gtsABCD* region were observed in all three endpoint  
19  
20 301 isolates as well as many intermediate isolates (66%, Figure 3B). Clear growth rate increases were  
21  
22 302 observed after acquiring one of these mutations (F2 → F21 in ALE5, F13 → F39 in ALE6, F1 →  
23  
24 303 F38 in ALE8, Figure 1E and 1F). These genes encode an ATP-binding cassette (ABC) sugar  
25  
26 304 transporting system, consisting of a sugar-binding protein (GtsA), two subunits of an ABC  
27  
28 305 transporter (GtsB and GtsC), and an ATP binding protein (GtsD); this system is known to transport  
29  
30 306 glucose into the cytosol through the inner membrane.<sup>40</sup> All endpoint clones acquired mutations in  
31  
32 307 *gtsA* (A100V, N304D, N304S, and A427V) and mutations in *gtsC* (F122L, L133F, and T238I)  
33  
34  
35 308 were observed only in clones from ALE8 (Figure S4B and S4C). Previously, it was observed that  
36  
37 309 mutations in *gtsABCD* allowed the transportation of xylose,<sup>43</sup> indicating its promiscuity in  
38  
39 310 transporting other compounds. Similarly, these frequent mutations in the *gtsABCD* region strongly  
40  
41 311 suggested that the major bottleneck was the transportation of galactose into the cytosol. In addition  
42  
43 312 to *gtsABCD*, two other regions related to glucose metabolism (*oprB-I/yeaD* and *oprB-II*) were also  
44  
45 313 commonly mutated (Figure 3B). OprB porins are known to transport glucose into the  
46  
47 314 periplasm.<sup>40,44</sup> Mutations in *oprB-I* (encoding carbohydrate-selective porin-I)/*yeaD* (encoding  
48  
49 315 glucose-6-phosphate 1-epimerase) regions were a stop codon insertion and frameshift in *oprB-I*,  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 316 or single nucleotide mutation in their intergenic region. Given that two *oprB-I* mutations are loss  
4  
5 317 of function mutations, it was inferred that its mutation was not beneficial for galactose utilization.  
6  
7 318 In *oprB-II*, a silent mutation (Y265Y) identically occurred in two endpoint isolates from ALE5  
8  
9 319 and ALE8 (Figure 3B) which displayed relatively higher galactose consumption rates compared  
10  
11 320 to the endpoint isolate from ALE6 (Figure 2F). The same mutation was also observed in previous  
12  
13 321 evolution studies with glucose,<sup>21,22</sup> suggesting that it likely improves the transport of hexoses into  
14  
15 322 the cytosol.  
16  
17  
18  
19 323

### 20 21 324 *3.2.2 Transcriptome analysis of evolved clones confirms the xylose and galactose utilization* 22 23 *pathways* 24 25

26 326 Transcriptomes of representative clones grown on xylose or galactose were analyzed to  
27  
28 327 better understand how these sugars are utilized via RNA-Seq. We focused on the expression level  
29  
30 328 changes of mutated genes and other endogenous genes in central carbon metabolism (Figure 3C)  
31  
32 329 and compared with the transcriptome of the wildtype KT2440 strain growing on glucose<sup>22</sup> as a  
33  
34 330 reference. In the four evolved *P. putida xylD* isolates analyzed, the expression levels of *ptxS*,  
35  
36 331 *kguETK*, and *ptxD* genes were indeed highly up-regulated, likely due to the derepression by PtxS  
37  
38 332 (Figure 3D). Specifically, the expression level of *kguT* was increased by 20.3-fold, on average,  
39  
40 333 when compared to that of the wildtype grown on glucose. Although a previous study suggested  
41  
42 334 that *gntT* is responsible for the transportation of xylonate,<sup>11</sup> its expression level was greatly  
43  
44 335 decreased, suggesting that xylonate is transported by KguT, and not GntT. Additionally, it was  
45  
46 336 observed that the expression levels of the PP\_2834-2837 genes were significantly increased (fold  
47  
48 337 changes > 500). One of these genes, PP\_2836, was previously suggested to encode 2-keto-3-  
49  
50 338 deoxy-xylonate dehydratase.<sup>10,11</sup> The upregulation of PP\_2836 supports the hypothesis on its role  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 339 to enable xylose metabolism via the Weimberg pathway. In addition to up-regulated genes, there  
4  
5 340 were also noteworthy down-regulated genes; given that xylose directly enters the TCA cycle after  
6  
7 341 its conversion to  $\alpha$ -ketoglutarate, genes related to glucose metabolism were relatively down-  
8  
9 342 regulated.

10  
11  
12 343 The expression levels in the three evolved *P. putida galETKM* strains were also  
13  
14 344 investigated to confirm the galactose utilization pathway and to investigate transcriptional changes  
15  
16 345 of three mutated regions (*gtsABCD*, *oprB-I/yeaD*, and *oprB-II*, Figure 3D). As expected, the  
17  
18 346 expression levels of *gtsABCD* were highly up-regulated (up to 9-fold) in the three isolates (Figure  
19  
20 347 3D), showing that they are closely related to the improved galactose utilization. The expression  
21  
22 348 levels of *oprB-I*, in which perceived loss-of-function mutations occurred, were commonly  
23  
24 349 increased (5.3-fold on average) while the *yeaD* expression levels changed inconsistently at lesser  
25  
26 350 extents. Notably, the expression levels of *oprB-II* were indeed increased in the two endpoint  
27  
28 351 isolates with the Y265Y mutation in this gene (the A5\_F85\_I1 and A8\_F92\_I1 strains) by 13.8-  
29  
30 352 fold and 9.7-fold, respectively (Figure 3B), whereas the level in the A6\_F90\_I1 without the  
31  
32 353 mutation decreased by 5.0-fold. This observation supports that this synonymous mutation,  
33  
34 354 upregulates its expression; previously, changed gene expression levels by synonymous mutations  
35  
36 355 have been observed in *Pseudomonas* species.<sup>45</sup> Furthermore, it was likely that this mutation also  
37  
38 356 affected the expression of a downstream gene, *gcd*, as its levels were similarly changed (5.6-fold  
39  
40 357 and 6.8-fold increases in the two strains with the mutation and a 3.7-fold decrease in the other  
41  
42 358 strain). The effect of *gcd* was further evaluated in a targeted analysis (see below). Additionally,  
43  
44 359 we compared the expression levels of the *galETKM* genes and their neighboring PP\_0871 and *prfC*  
45  
46 360 genes (Figure S6) to investigate potential transcriptional changes caused by the two mutations in  
47  
48 361 the A8\_F92\_I1 stain (Supplementary Data 3). However, the levels in the A8\_F92\_I1 strain were  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 362 generally similar to those in A5\_F85\_I1, which do not have any mutations in this region, indicating  
4  
5 363 that they do not significantly affect the transcription levels.  
6  
7

8 364

9  
10  
11 365 **Reverse engineering validates the xylose and galactose utilization pathways and phenotypes**

12  
13 366 The essentiality of the heterologous and mutated genes was examined via gene deletions  
14  
15 367 and subsequent growth measurements on the constructed clones. Initially, the heterologous *xyID*  
16  
17 368 or *galETKM* gene was deleted in the A1\_F11\_I1 strain and A6\_F90\_I1 strain, respectively.  
18  
19 369 Unsurprisingly, the A1\_F11\_I1\_Δ*xyID* and A6\_F90\_I1\_Δ*galETKM* strains completely lost their  
20  
21 370 capability to grow on xylose or galactose (Figure 4A and 4B), respectively, confirming the  
22  
23 371 essentiality of these genes. It is worthwhile to note that despite the presence of an endogenous  
24  
25 372 *fucD* encoding fuconate dehydratase (which was significantly overexpressed by on average 62.6-  
26  
27 373 fold, Figure 3D), this potential promiscuous activity could not support xylose-based growth in the  
28  
29 374 strain. Next, we validated the roles of two frequently mutated genes (*kguT* and *gtsABCD*). As  
30  
31 375 expected, the A1\_F11\_I1\_Δ*kguT* and A6\_F90\_I1\_Δ*gtsABCD* strains lacking the mutated  
32  
33 376 transporter could not grow on xylose or galactose, respectively, confirming that these sugar  
34  
35 377 transporters are indeed critical to the sugar metabolism. Collectively, these results indicate that  
36  
37 378 xylose and galactose are utilized via the introduced Weimberg and Leloir pathways, respectively,  
38  
39 379 and KguT and GtsABCD are essential for their respective sugar metabolism.  
40  
41  
42  
43  
44

45 380 The effect and removal of *gcd* was evaluated in evolved strains given its significant  
46  
47 381 upregulation and its known role in generating growth-inhibiting dead-end byproducts due to its  
48  
49 382 broad substrate specificity.<sup>8,12,46</sup> Clones A5\_F85\_I1 and A8\_F92\_I1 were evaluated using a  
50  
51 383 deletion of *gcd* for this analysis as their growth was arrested before full galactose consumption  
52  
53 384 during phenotypic characterization (Figure 2E). Indeed, after the deletion of *gcd*, the two strains  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 385 (A5\_F85\_I1\_Δ*gcd* and A8\_F92\_I1\_Δ*gcd*) showed significantly increased biomass formation and  
4  
5 386 galactose consumption (Figure 4C). The final OD<sub>600</sub> reached 2.69 and 2.67 and 4 g/L galactose  
6  
7 387 was fully consumed during 24 h, respectively. Galactose uptake rates were 0.85 g/g DCW/h and  
8  
9 388 1.61 g/g DCW/h, respectively, which is a slight reduction versus their parent strains over the same  
10  
11 389 time window. Overall, these results confirmed that *gcd* overexpression induced stunted growth of  
12  
13 390 the two evolved isolates and this phenomenon was not observed in clone A6\_F90\_I1, which did  
14  
15 391 not possess a mutation in the neighboring *oprB*-II.  
16  
17  
18  
19  
20  
21  
22

392

### 393 **Production of indigoidine with the evolved isolates**

23  
24  
25 394 The applicability of the evolved strains and further *gcd*-deleted strains as preferred host  
26  
27 395 chassis for the biochemical production of indigoidine from either xylose or galactose was  
28  
29 396 examined. In particular, the Δ*gcd* strains were included, given that the deletion did not significantly  
30  
31 397 affect the growth rates on glucose (Figure S3). For this demonstration, we introduced the  
32  
33 398 production pathway of indigoidine, which is a natural pigment and has industrial interest,<sup>14,47,48</sup> in  
34  
35 399 evolved isolates (Figure 5A). It was previously shown that indigoidine can be produced by the  
36  
37 400 heterologous expression of *bpsA* encoding blue pigment synthetase A from *Streptomyces*  
38  
39 401 *lavendulae* and *sfp* encoding 4'-phosphopantetheinyl transferase from *Bacillus subtilis*.<sup>14,47</sup> We  
40  
41 402 expressed the two genes under the arabinose-inducible promoter and integrated them into the  
42  
43 403 genome (see Methods). Subsequently, the resulting strains were cultivated in minimal media  
44  
45 404 supplemented with 10 g/L xylose or galactose. The cultivation showed that all evolved strains with  
46  
47 405 the heterologous production pathway successfully produced indigoidine, whereas the starting  
48  
49 406 strain with the pathway did not produce a detectable amount of indigoidine (Figure 5B and Figure  
50  
51 407 S7). The titers varied, on average  $2.5 \pm 0.8$  g/L for xylose and  $0.8 \pm 0.5$  g/L for galactose at 48 h,  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 408 depending on the sugar source and host, indicating that the use of different sugars and host  
4  
5 409 genotypes significantly affect the production. Specifically, xylose utilization via the Weimberg  
6  
7 410 pathway allowed much higher indigoidine titers (3.1-fold on average) compared to the galactose  
8  
9 411 utilization via the Leloir pathway. Among them, the A2\_F10\_I1\_indigoidine strain produced 3.2  
10  
11 412 g/L, which is a higher value than the titer (1.5 - 2 g/L) from the same amount of glucose.<sup>14</sup> The  
12  
13 413 titer of 2.2 g/L achieved by the A6\_F90\_I1 strain was also comparable, while the other two strains  
14  
15 414 did not show high titers, probably due to the stalled growth and galactose consumption (Figure 4).  
16  
17 415 Both  $\Delta gcd$  strains showed improved indigoidine production compared to their parental strains, but  
18  
19 416 the titers were still less than that achieved with the A6\_F90\_I1 strain. The highest titers for each  
20  
21 417 carbon source represent up to 43% and 29% of the maximum theoretical production (see Methods  
22  
23 418 for calculation). Collectively, this successful demonstration of the indigoidine production supports  
24  
25 419 the applicability of the evolved clones in various biochemical production processes as optimized  
26  
27 420 chassis when compared to the initial engineered, but unevolved counterparts.  
28  
29  
30  
31  
32

33 421

#### 35 422 **4. Discussion**

37 423 To develop economically feasible bioprocesses, it is essential to utilize host  
38  
39 424 microorganisms that efficiently utilize carbon sources available from biomass.<sup>49-51</sup> However, often  
40  
41 425 the catabolic activities of wildtype microorganisms are not high enough, and require further  
42  
43 426 engineering. While there are many successful studies showing that rationally engineered  
44  
45 427 microorganisms improve the utilization of native or non-native carbon sources,<sup>4,52-54</sup> an initial  
46  
47 428 design could fail or result in unsatisfactory utilization due to the inability to precisely engineer a  
48  
49 429 microorganism. In this regard, our study demonstrated that an ALE strategy can complement a  
50  
51 430 rational strain design strategy and generate improved strains by efficiently seeking beneficial  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 431 mutations from a large sequence space. Additionally, we showed that ALE allows for a deeper  
4  
5 432 understanding of host microorganisms by performing multi-scale analyses of evolved and reverse  
6  
7 433 engineered strains. The genome and transcriptome sequencing of independently evolved clones  
8  
9 434 were crucial to understand how xylose and galactose are catabolized and to identify rate-limiting  
10  
11 435 steps in KT2440. In addition, the analysis was also important to understand the range of  
12  
13 436 phenotypes possible in evolved clones and was utilized to further engineer the strains.  
14  
15

16  
17 437         Interestingly, the final growth rates of *P. putida xylD* evolved clones on xylose (0.23-0.25  
18  
19 438 h<sup>-1</sup>) were relatively slower than those of *P. putida galETKM* on galactose (0.35-0.52 h<sup>-1</sup>). Similarly,  
20  
21 439 different endpoint growth rates depending on sugars were also observed in a previous ALE study  
22  
23 440 with *E. coli* K-12 MG1655.<sup>55</sup> Potentially, the xylose oxidation activity of Gcd could be another  
24  
25 441 rate-limiting step given xylose is likely not a native substrate.<sup>56,57</sup> Although it is not currently clear  
26  
27 442 why the growth rates on xylose remained at low levels and were not further improved, considering  
28  
29 443 that typical biomass hydrolysates contain multiple sugars, the *P. putida xylD* clones could consume  
30  
31 444 other sugars (e.g., glucose, Figure S3) and show higher growth rates during fermentation with  
32  
33 445 actual biomass-derived feedstocks. If even higher growth rates are desired, further ALE  
34  
35 446 experiments with increased mutation rates or combining multiple catabolic pathways could be  
36  
37 447 performed. Growth rates on glucose greater than 0.8 h<sup>-1</sup> have been observed in previous ALE  
38  
39 448 studies.<sup>21,22</sup> Finally, the finding that similar growth rates of the evolved clones to the wild type on  
40  
41 449 glucose (Figure S3) indicates that the evolved strains are not entirely specialized and the mutations  
42  
43 450 they possess appear to be local to the targeted sugar uptake pathways.  
44  
45

46  
47 451         Additionally, more value can be added if the simultaneous utilization of multiple sugars is  
48  
49 452 studied and ALE can similarly aid in the optimization of such strains. A bioprocess for the  
50  
51 453 simultaneous utilization can be directly designed by co-culturing the generated strains for the  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 454 specified utilization of sugars.<sup>58,59</sup> More promisingly, separately evolved and optimized pathways  
4  
5 455 and mutations could be introduced into a single strain and inherent preferential utilization  
6  
7 456 mechanisms can be deregulated. Previously, the deletion of carbon catabolite repression protein  
8  
9  
10 457 (Cre) was shown to enable the simultaneous utilization of sugars and aromatics.<sup>16</sup> Alternatively,  
11  
12 458 one can also apply another ALE strategy that grows a strain under a substrate-switching condition  
13  
14 459 or mixed-substrate condition<sup>55,60</sup> to facilitate the utilization of multiple sugars. These efforts have  
15  
16  
17 460 the potentially to greatly improve titers, productivities, and yields by increasing the substrate  
18  
19 461 consumption rate (i.e., front end engineering), which are critical measures in bioprocess.

20  
21 462 In summary, we successfully generated *P. putida* KT2440 strains for the efficient  
22  
23 463 utilization of xylose and galactose. The ALE approach successfully overcomes the limitation of  
24  
25 464 rational strain design and enabled significantly improved xylose and galactose utilization  
26  
27 465 capabilities. Furthermore, our indigoidine production results show the strong potential of the  
28  
29 466 developed strains to improve the economic viability. We believe the developed strains as well as  
30  
31 467 mutational mechanisms could be useful for developing efficient biomass-converting processes.

32 468

### 33 469 **Acknowledgements**

34  
35  
36  
37  
38 470 This work conducted by the Joint BioEnergy Institute was supported by the Office of  
39  
40 471 Science, Office of Biological and Environmental Research, of the U.S. Department of Energy  
41  
42 472 under Contract No. DE-AC02-05CH11231. We would like to appreciate Dr. José Henrique Pereira,  
43  
44 473 Joshua Mueller, and Patrick V. Phaneuf for helpful discussion. We also thank Connor A. Olson,  
45  
46 474 Richard Szubin, Ying Hutchison, and Marc K. Abrams for technical support and manuscript  
47  
48 475 editing.

49 476

1  
2  
3 477 **Conflict of Interest**  
4

5 478 Hyun Gyu Lim, Adam M. Feist, and Thomas Eng are the inventors of U.S. Provisional  
6  
7 479 Application Serial No. 63/168,687 based on this study. The other authors declare no competing  
8  
9 financial interest.  
10

11  
12 481

13  
14  
15 482 **Supporting Information**  
16

17 483 Figure S1. Pathways for glucose, xylose, and galactose utilization  
18

19 484 Figure S2. Growth profiles of the wildtype KT2440 and engineered strains on xylose and galactose  
20

21 485 Figure S3. Growth rate comparison of the wildtype KT2440 and evolved strains on glucose  
22

23 486 Figure S4. I-TASSER predicted structures of KguT, GtsA, and GtsC and their mutations  
24

25 487 Figure S5. Cluster of orthologous groups (COG) analysis of commonly differentially expressed  
26  
27 488 genes  
28

29  
30 489 Figure S6. Transcripts per million of the *galETKM* genes and their neighboring genes  
31

32 490 Figure S7. Standard curve for indigoidine quantification  
33

34  
35 491

36  
37 492 Table S1. Previous studies for enabling non-native sugars in *P. putida* strains  
38

39 493 Table S2. Stains used in this study  
40

41 494 Table S3. Plasmids used in this study  
42

43 495 Table S4. Oligonucleotides used in this study  
44

45 496 Table S5. Summary of the ALE experiments  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

497 **References**

- 498 (1) Nickel, P. I.; de Lorenzo, V. *Pseudomonas putida* as a functional chassis for industrial  
499 biocatalysis: From native biochemistry to trans-metabolism. *Metab. Eng.* **2018**, *50*, 142–  
500 155.
- 501 (2) Belda, E.; van Heck, R. G. A.; José Lopez-Sanchez, M.; Cruveiller, S.; Barbe, V.; Fraser,  
502 C.; Klenk, H.-P.; Petersen, J.; Morgat, A.; Nickel, P. I.; et al. The revisited genome of  
503 *Pseudomonas putida* KT2440 enlightens its value as a robust metabolic chassis. *Environ.*  
504 *Microbiol.* **2016**, *18*, 3403–3424.
- 505 (3) Nogales, J.; Mueller, J.; Gudmundsson, S.; Canalejo, F. J.; Duque, E.; Monk, J.; Feist, A.  
506 M.; Ramos, J. L.; Niu, W.; Palsson, B. O. High-quality genome-scale metabolic modelling  
507 of *Pseudomonas putida* highlights its broad metabolic capabilities. *Environ. Microbiol.*  
508 **2020**, *22*, 255–269.
- 509 (4) Lim, H. G.; Seo, S. W.; Jung, G. Y. Engineered *Escherichia coli* for simultaneous utilization  
510 of galactose and glucose. *Bioresour. Technol.* **2013**, *135*, 564–567.
- 511 (5) Isikgor, F. H.; Becer, C. R. Lignocellulosic biomass: a sustainable platform for the  
512 production of bio-based chemicals and polymers. *Polym. Chem.* **2015**, *6*, 4497–4559.
- 513 (6) Meijnen, J.-P.; de Winde, J. H.; Ruijssenaars, H. J. Engineering *Pseudomonas putida* S12  
514 for efficient utilization of D-xylose and L-arabinose. *Appl. Environ. Microbiol.* **2008**, *74*,  
515 5031–5037.
- 516 (7) Le Meur, S.; Zinn, M.; Egli, T.; Thöny-Meyer, L.; Ren, Q. Production of medium-chain-  
517 length polyhydroxyalkanoates by sequential feeding of xylose and octanoic acid in  
518 engineered *Pseudomonas putida* KT2440. *BMC Biotechnol.* **2012**, *12*, 53.



- 1  
2  
3 519 (8) Dvořák, P.; de Lorenzo, V. Refactoring the upper sugar metabolism of *Pseudomonas putida*  
4  
5 520 for co-utilization of cellobiose, xylose, and glucose. *Metab. Eng.* **2018**, *48*, 94–108.  
6  
7  
8 521 (9) Wang, Y.; Horlamus, F.; Henkel, M.; Kovacic, F.; Schläfle, S.; Hausmann, R.; Wittgens,  
9  
10 522 A.; Rosenau, F. Growth of engineered *Pseudomonas putida* KT2440 on glucose, xylose and  
11  
12 523 arabinose: hemicellulose hydrolysates and their major sugars as sustainable carbon sources.  
13  
14 524 *Glob. Change Biol. Bioenergy* **2019**.  
15  
16  
17 525 (10) Bator, I.; Wittgens, A.; Rosenau, F.; Tiso, T.; Blank, L. M. Comparison of Three Xylose  
18  
19 526 Pathways in *Pseudomonas putida* KT2440 for the Synthesis of Valuable Products. *Front.*  
20  
21 527 *Bioeng. Biotechnol.* **2019**, *7*, 480.  
22  
23  
24 528 (11) Meijnen, J.-P.; de Winde, J. H.; Ruijsenaars, H. J. Establishment of oxidative D-xylose  
25  
26 529 metabolism in *Pseudomonas putida* S12. *Appl. Environ. Microbiol.* **2009**, *75*, 2784–2791.  
27  
28  
29 530 (12) Shen, L.; Kohlhaas, M.; Enoki, J.; Meier, R.; Schönenberger, B.; Wohlgemuth, R.; Kourist,  
30  
31 531 R.; Niemeyer, F.; van Niekerk, D.; Bräsen, C.; et al. A combined experimental and  
32  
33 532 modelling approach for the Weimberg pathway optimisation. *Nat. Commun.* **2020**, *11*, 1098.  
34  
35  
36 533 (13) Peabody, G. L.; Elmore, J. R.; Martinez-Baird, J.; Guss, A. M. Engineered *Pseudomonas*  
37  
38 534 *putida* KT2440 co-utilizes galactose and glucose. *Biotechnol Biofuels* **2019**, *12*, 295.  
39  
40  
41 535 (14) Banerjee, D.; Eng, T.; Lau, A. K.; Sasaki, Y.; Wang, B.; Chen, Y.; Prahl, J.-P.; Singan, V.  
42  
43 536 R.; Herbert, R. A.; Liu, Y.; et al. Genome-scale metabolic rewiring improves titers rates  
44  
45 537 and yields of the non-native product indigoidine at scale. *Nat. Commun.* **2020**, *11*, 5385.  
46  
47  
48 538 (15) Kang, C. W.; Lim, H. G.; Yang, J.; Noh, M. H.; Seo, S. W.; Jung, G. Y. Synthetic  
49  
50 539 auxotrophs for stable and tunable maintenance of plasmid copy number. *Metab. Eng.* **2018**,  
51  
52 540 *48*, 121–128.  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 541 (16) Elmore, J. R.; Dexter, G. N.; Salvachúa, D.; O'Brien, M.; Klingeman, D. M.; Gorday, K.;  
4  
5 542 Michener, J. K.; Peterson, D. J.; Beckham, G. T.; Guss, A. M. Engineered *Pseudomonas*  
6  
7 543 *putida* simultaneously catabolizes five major components of corn stover lignocellulose:  
8  
9 544 Glucose, xylose, arabinose, p-coumaric acid, and acetic acid. *Metab. Eng.* **2020**, *62*, 62–71.
- 10  
11  
12 545 (17) Sandberg, T. E.; Salazar, M. J.; Weng, L. L.; Palsson, B. O.; Feist, A. M. The emergence  
13  
14 546 of adaptive laboratory evolution as an efficient tool for biological discovery and industrial  
15  
16 547 biotechnology. *Metab. Eng.* **2019**, *56*, 1–16.
- 17  
18  
19 548 (18) LaCroix, R. A.; Palsson, B. O.; Feist, A. M. A model for designing adaptive laboratory  
20  
21 549 evolution experiments. *Appl. Environ. Microbiol.* **2017**, *83*.
- 22  
23  
24 550 (19) Wong, B. G.; Mancuso, C. P.; Kiriakov, S.; Bashor, C. J.; Khalil, A. S. Precise, automated  
25  
26 551 control of conditions for high-throughput growth of yeast and bacteria with eVOLVER.  
27  
28 552 *Nat. Biotechnol.* **2018**, *36*, 614–623.
- 29  
30  
31 553 (20) Mohamed, E. T.; Wang, S.; Lennen, R. M.; Herrgård, M. J.; Simmons, B. A.; Singer, S.  
32  
33 554 W.; Feist, A. M. Generation of a platform strain for ionic liquid tolerance using adaptive  
34  
35 555 laboratory evolution. *Microb. Cell Fact.* **2017**, *16*, 204.
- 36  
37  
38 556 (21) Mohamed, E. T.; Werner, A. Z.; Salvachúa, D.; Singer, C. A.; Szostkiewicz, K.; Rafael  
39  
40 557 Jiménez-Díaz, M.; Eng, T.; Radi, M. S.; Simmons, B. A.; Mukhopadhyay, A.; et al.  
41  
42 558 Adaptive laboratory evolution of *Pseudomonas putida* KT2440 improves p-coumaric and  
43  
44 559 ferulic acid catabolism and tolerance. *Metab. Eng. Commun.* **2020**, *11*, e00143.
- 45  
46  
47 560 (22) Lim, H. G.; Fong, B.; Alarcon, G.; Magurudeniya, H. D.; Eng, T.; Szubin, R.; Olson, C.  
48  
49 561 A.; Palsson, B. O.; Gladden, J. M.; Simmons, B. A.; et al. Generation of ionic liquid tolerant  
50  
51 562 *Pseudomonas putida* KT2440 strains via adaptive laboratory evolution. *Green Chem.* **2020**,  
52  
53 563 *22*, 5677–5690.

- 1  
2  
3 564 (23) Nguyen-Vo, T. P.; Liang, Y.; Sankaranarayanan, M.; Seol, E.; Chun, A. Y.; Ashok, S.;  
4  
5 565 Chauhan, A. S.; Kim, J. R.; Park, S. Development of 3-hydroxypropionic-acid-tolerant  
6  
7 566 strain of *Escherichia coli* W and role of minor global regulator yieP. *Metab. Eng.* **2019**, *53*,  
8  
9 567 48–58.
- 10  
11  
12 568 (24) Guzmán, G. I.; Sandberg, T. E.; LaCroix, R. A.; Nyerges, Á.; Papp, H.; de Raad, M.; King,  
13  
14 569 Z. A.; Hefner, Y.; Northen, T. R.; Notebaart, R. A.; et al. Enzyme promiscuity shapes  
15  
16 570 adaptation to novel growth substrates. *Mol. Syst. Biol.* **2019**, *15*, e8462.
- 17  
18  
19 571 (25) Mohamed, E. T.; Mundhada, H.; Landberg, J.; Cann, I.; Mackie, R. I.; Nielsen, A. T.;  
20  
21 572 Herrgård, M. J.; Feist, A. M. Generation of an *E. coli* platform strain for improved sucrose  
22  
23 573 utilization using adaptive laboratory evolution. *Microb. Cell Fact.* **2019**, *18*, 116.
- 24  
25  
26 574 (26) Reider Apel, A.; Ouellet, M.; Szmidt-Middleton, H.; Keasling, J. D.; Mukhopadhyay, A.  
27  
28 575 Evolved hexose transporter enhances xylose uptake and glucose/xylose co-utilization in  
29  
30 576 *Saccharomyces cerevisiae*. *Sci. Rep.* **2016**, *6*, 19512.
- 31  
32  
33 577 (27) Takahashi, H.; Kumagai, T.; Kitani, K.; Mori, M.; Matoba, Y.; Sugiyama, M. Cloning and  
34  
35 578 characterization of a *Streptomyces* single module type non-ribosomal peptide synthetase  
36  
37 579 catalyzing a blue pigment synthesis. *J. Biol. Chem.* **2007**, *282*, 9073–9081.
- 38  
39  
40 580 (28) Seo, S. W.; Yang, J.-S.; Kim, I.; Yang, J.; Min, B. E.; Kim, S.; Jung, G. Y. Predictive design  
41  
42 581 of mRNA translation initiation region to control prokaryotic translation efficiency. *Metab.*  
43  
44 582 *Eng.* **2013**, *15*, 67–74.
- 45  
46  
47 583 (29) Deatherage, D. E.; Barrick, J. E. Identification of mutations in laboratory-evolved microbes  
48  
49 584 from next-generation sequencing data using breseq. *Methods Mol. Biol.* **2014**, *1151*, 165–  
50  
51 585 188.
- 52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 586 (30) Langmead, B.; Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nat. Methods*  
4  
5 587 **2012**, *9*, 357–359.  
6  
7  
8 588 (31) Phaneuf, P. V.; Gosting, D.; Palsson, B. O.; Feist, A. M. ALEdb 1.0: a database of mutations  
9  
10 589 from adaptive laboratory evolution experimentation. *Nucleic Acids Res.* **2019**, *47*, D1164–  
11  
12 590 D1171.  
13  
14  
15 591 (32) Lawrence, M.; Huber, W.; Pagès, H.; Aboyoun, P.; Carlson, M.; Gentleman, R.; Morgan,  
16  
17 592 M. T.; Carey, V. J. Software for computing and annotating genomic ranges. *PLoS Comput.*  
18  
19 593 *Biol.* **2013**, *9*, e1003118.  
20  
21  
22 594 (33) Love, M. I.; Huber, W.; Anders, S. Moderated estimation of fold change and ' ' dispersion  
23  
24 595 for RNA-seq data with DESeq2. *Genome Biol.* **2014**, *15*, 550.  
25  
26  
27 596 (34) Yu, D.; Xu, F.; Valiente, J.; Wang, S.; Zhan, J. An indigoidine biosynthetic gene cluster  
28  
29 597 from *Streptomyces chromofuscus* ATCC 49982 contains an unusual IndB homologue. *J.*  
30  
31 598 *Ind. Microbiol. Biotechnol.* **2013**, *40*, 159–168.  
32  
33  
34 599 (35) Sandberg, T. E.; Szubin, R.; Phaneuf, P. V.; Palsson, B. O. Synthetic cross-phyla gene  
35  
36 600 replacement and evolutionary assimilation of major enzymes. *Nat. Ecol. Evol.* **2020**.  
37  
38  
39 601 (36) Li, G.-M. Mechanisms and functions of DNA mismatch repair. *Cell Res.* **2008**, *18*, 85–98.  
40  
41  
42 602 (37) Del Castillo, T.; Duque, E.; Ramos, J. L. A set of activators and repressors control  
43  
44 603 peripheral glucose pathways in *Pseudomonas putida* to yield a common central intermediate.  
45  
46 604 *J. Bacteriol.* **2008**, *190*, 2331–2339.  
47  
48  
49 605 (38) Swanson, B. L.; Hager, P.; Phibbs, P.; Ochsner, U.; Vasil, M. L.; Hamood, A. N.  
50  
51 606 Characterization of the 2-ketogluconate utilization operon in *Pseudomonas aeruginosa*  
52  
53 607 PAO1. *Mol. Microbiol.* **2000**, *37*, 561–573.  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 608 (39) Udaondo, Z.; Ramos, J.-L.; Segura, A.; Krell, T.; Daddaoua, A. Regulation of carbohydrate  
4  
5 609 degradation pathways in *Pseudomonas* involves a versatile set of transcriptional regulators.  
6  
7 610 *Microb Biotechnol* **2018**, *11*, 442–454.
- 8  
9  
10 611 (40) Meijnen, J.-P.; de Winde, J. H.; Ruijsenaars, H. J. Metabolic and regulatory  
11  
12 612 rearrangements underlying efficient D-xylose utilization in engineered *Pseudomonas*  
13  
14 613 *putida* S12. *J. Biol. Chem.* **2012**, *287*, 14606–14614.
- 15  
16  
17 614 (41) Saravolac, E. G.; Taylor, N. F.; Benz, R.; Hancock, R. E. Purification of glucose-inducible  
18  
19 615 outer membrane protein OprB of *Pseudomonas putida* and reconstitution of glucose-  
20  
21 616 specific pores. *J. Bacteriol.* **1991**, *173*, 4970–4976.
- 22  
23  
24 617 (42) Bailey, S. F.; Hinz, A.; Kassen, R. Adaptive synonymous mutations in an experimentally  
25  
26 618 evolved *Pseudomonas fluorescens* population. *Nat. Commun.* **2014**, *5*, 4076.
- 27  
28  
29 619 (43) Dokter, P.; Pronk, J. T.; Schie, B. J.; Dijken, J. P.; Duine, J. A. The in vivo and in vitro  
30  
31 620 substrate specificity of quinoprotein glucose dehydrogenase of *Acinetobacter calcoaceticus*  
32  
33 621 LMD79.41. *FEMS Microbiol. Lett.* **1987**, *43*, 195–200.
- 34  
35  
36 622 (44) Wehrs, M.; Gladden, J. M.; Liu, Y.; Platz, L.; Prahl, J.-P.; Moon, J.; Papa, G.; Sundstrom,  
37  
38 623 E.; Geiselman, G. M.; Tanjore, D.; et al. Sustainable bioproduction of the blue pigment  
39  
40 624 indigoidine: Expanding the range of heterologous products in *R. toruloides* to include non-  
41  
42 625 ribosomal peptides. *Green Chem.* **2019**, *21*, 3394–3406.
- 43  
44  
45 626 (45) Wehrs, M.; Prahl, J.-P.; Moon, J.; Li, Y.; Tanjore, D.; Keasling, J. D.; Pray, T.;  
46  
47 627 Mukhopadhyay, A. Production efficiency of the bacterial non-ribosomal peptide  
48  
49 628 indigoidine relies on the respiratory metabolic state in *S. cerevisiae*. *Microb. Cell Fact.*  
50  
51 629 **2018**, *17*, 193.
- 52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 630 (46) Lim, H. G.; Kwak, D. H.; Park, S.; Woo, S.; Yang, J. S.; Kang, C. W.; Kim, B.; Noh, M.  
4  
5 631 H.; Seo, S. W.; Jung, G. Y. *Vibrio* sp. dhg as a platform for the biorefinery of brown  
6  
7 632 macroalgae. *Nat. Commun.* **2019**, *10*, 2486.  
8  
9  
10 633 (47) Linger, J. G.; Vardon, D. R.; Guarnieri, M. T.; Karp, E. M.; Hunsinger, G. B.; Franden, M.  
11  
12 634 A.; Johnson, C. W.; Chupka, G.; Strathmann, T. J.; Pienkos, P. T.; et al. Lignin valorization  
13  
14 635 through integrated biological funneling and chemical catalysis. *Proc. Natl. Acad. Sci. USA*  
15  
16 636 **2014**, *111*, 12013–12018.  
17  
18  
19 637 (48) Yaegashi, J.; Kirby, J.; Ito, M.; Sun, J.; Dutta, T.; Mirsiaghi, M.; Sundstrom, E. R.;  
20  
21 638 Rodriguez, A.; Baidoo, E.; Tanjore, D.; et al. Rhodosporidium toruloides: a new platform  
22  
23 639 organism for conversion of lignocellulose into terpene biofuels and bioproducts. *Biotechnol*  
24  
25 640 *Biofuels* **2017**, *10*, 241.  
26  
27  
28 641 (49) Wargacki, A. J.; Leonard, E.; Win, M. N.; Regitsky, D. D.; Santos, C. N. S.; Kim, P. B.;  
29  
30 642 Cooper, S. R.; Raisner, R. M.; Herman, A.; Sivitz, A. B.; et al. An engineered microbial  
31  
32 643 platform for direct biofuel production from brown macroalgae. *Science* **2012**, *335*, 308–  
33  
34 644 313.  
35  
36  
37 645 (50) Antonovsky, N.; Gleizer, S.; Noor, E.; Zohar, Y.; Herz, E.; Barenholz, U.; Zelcbuch, L.;  
38  
39 646 Amram, S.; Wides, A.; Tepper, N.; et al. Sugar Synthesis from CO<sub>2</sub> in *Escherichia coli*.  
40  
41 647 *Cell* **2016**, *166*, 115–125.  
42  
43  
44 648 (51) Enquist-Newman, M.; Faust, A. M. E.; Bravo, D. D.; Santos, C. N. S.; Raisner, R. M.;  
45  
46 649 Hanel, A.; Sarvabhowman, P.; Le, C.; Regitsky, D. D.; Cooper, S. R.; et al. Efficient ethanol  
47  
48 650 production from brown macroalgae sugars by a synthetic yeast platform. *Nature* **2014**, *505*,  
49  
50 651 239–243.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 652 (52) Sandberg, T. E.; Lloyd, C. J.; Palsson, B. O.; Feist, A. M. Laboratory evolution to  
4  
5 653 alternating substrate environments yields distinct phenotypic and genetic adaptive  
6  
7 654 strategies. *Appl. Environ. Microbiol.* **2017**, *83*.
- 8  
9  
10 655 (53) Sharma, V.; Kumar, V.; Archana, G.; Kumar, G. N. Substrate specificity of glucose  
11  
12 656 dehydrogenase (GDH) of *Enterobacter asburiae* PSI3 and rock phosphate solubilization  
13  
14 657 with GDH substrates as C sources. *Can. J. Microbiol.* **2005**, *51*, 477–482.
- 15  
16  
17 658 (54) Igarashi, S.; Hirokawa, T.; Sode, K. Engineering PQQ glucose dehydrogenase with  
18  
19 659 improved substrate specificity. Site-directed mutagenesis studies on the active center of  
20  
21 660 PQQ glucose dehydrogenase. *Biomol Eng* **2004**, *21*, 81–89.
- 22  
23  
24 661 (55) Wang, L.; York, S. W.; Ingram, L. O.; Shanmugam, K. T. Simultaneous fermentation of  
25  
26 662 biomass-derived sugars to ethanol by a co-culture of an engineered *Escherichia coli* and  
27  
28 663 *Saccharomyces cerevisiae*. *Bioresour. Technol.* **2019**, *273*, 269–276.
- 29  
30  
31 664 (56) Zhang, H.; Pereira, B.; Li, Z.; Stephanopoulos, G. Engineering *Escherichia coli* coculture  
32  
33 665 systems for the production of biochemical products. *Proc. Natl. Acad. Sci. USA* **2015**, *112*,  
34  
35 666 8266–8271.
- 36  
37  
38 667 (57) Quan, S.; Ray, J. C. J.; Kwota, Z.; Duong, T.; Balázsi, G.; Cooper, T. F.; Monds, R. D.  
39  
40 668 Adaptive evolution of the lactose utilization network in experimentally evolved populations  
41  
42 669 of *Escherichia coli*. *PLoS Genet.* **2012**, *8*, e1002444.
- 43  
44  
45 670 (58) Lee, D.-H.; Feist, A. M.; Barrett, C. L.; Palsson, B. Ø. Cumulative number of cell divisions  
46  
47 671 as a meaningful timescale for adaptive laboratory evolution of *Escherichia coli*. *PLoS One*  
48  
49 672 **2011**, *6*, e26172.

673

674

675 **Table**676 **Table 1. Commonly mutated genes and regions in evolved strains**


Region	Gene product	Frequency (total samples)	Number of unique mutations
<i>P. putida xylD</i>		<i>n</i> = 11	
<i>ptxS</i>	Ketogluconate utilization operon repressor	100% (ALE1-4)	5
<i>kguT</i>	2-Ketogluconate transporter	82% (ALE1-4)	9
<i>gacS</i>	Sensor protein	36% (ALE2 and ALE3)	3
<i>ftsH</i>	Integral membrane ATP-dependent zinc metallopeptidase	27% (ALE2 and ALE4)	3
PP_4173	Two-component system sensor histidine kinase/response regulator	27% (ALE1 and ALE2)	3
<i>galP-I</i> /PP_1174	Porin-like protein/hypothetical protein	18% (ALE2 and ALE4)	2
<i>P. putida galETKM</i>		<i>n</i> = 12	
<i>gtsABCD</i>	Mannose/glucose ABC transporter	66% (ALE5, ALE6, ALE8)	7
<i>oprB-I/yeaD</i>	Carbohydrate-selective porin-I/glucose-6-phosphate 1-epimerase	58% (ALE5, ALE6, ALE8)	4
<i>oprB-II</i>	Carbohydrate-selective porin-II	17% (ALE5 and ALE8)	1

677

678

679




680 **Figure caption**681 **Figure 1. Adaptive Laboratory Evolution (ALE) strategies for improving xylose and**  
682 **galactose utilization**

683  
684 **(A and B)** The ALE strategies to evolve the *P. putida xylD* and *P. putida galETKM* strains. Growth  
685 trajectories of **(C)** ALE1-4 and **(D)** ALE5, ALE6, and ALE8 with the *xylD* and *galETKM* strains,  
686 respectively. The *x*-axis and *y*-axis indicate Cumulative Cell Divisions (CCD)<sup>61</sup> and the maximum  
687 specific growth rate (h<sup>-1</sup>). CCD for the galactose ALE experiments were calculated from the first


1  
2  
3 688 flask which displayed an observable growth rate solely on galactose minimal media. Comparisons  
4  
5 689 of the maximum specific growth rates ( $h^{-1}$ ) of isolated clones from different evolutionary  
6  
7 690 timepoints of **(E)** ALE1-4 and **(F)** ALE5, ALE6, and ALE8. Cell cultures were conducted in  
8  
9  
10 691 biological duplicates and error bars indicate the minimum and maximum values.  
11

12 692  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

693 **Figure 2. Growth profiles of the wildtype KT2440 and evolved isolates**




694  
 695 (A) Growth, (B) xylose consumption, (C) xylose uptake rates and biomass yields of the *P. putida*  
 696 *xyID* strain and evolved isolates in the xylose minimal medium during a 24 h cultivation. (D)  
 697 Growth, (E) galactose consumption, (F) galactose uptake rates and biomass yields of the *P. putida*  
 698 *galETKM* strain and evolved isolates on galactose in the galactose minimal medium during a 24 h  
 699 cultivation. (A, B, D, E) *x*-axis indicates time (h) and left *y*-axis indicates (A and D) OD<sub>600</sub> or (B  
 700 and E) sugar concentration (g/L). (C and F) left and right *y*-axis indicates sugar consumption rate  
 701 during the exponential growth phase and biomass yield, respectively. The cultures were conducted  
 702 with three biological replicates (*n*=3) and error bars indicate the standard deviations.

703 **Figure 3. Genomic and transcriptomic analysis of evolved isolates**

704  
 705 **(A and B)** Identified mutations in **(A)** the *ptxS-kguEKT-ptxD* region of evolved *P. putida xylD*  
 706 clones and **(B)** the *gtsA-gtsBCD-oprB-I-yeaD* and *oprB-II-gcd* regions of evolved *P. putida*  
 707 *galETKM* clones. **(A and B)** Uppercase and lowercase letters indicate amino acids and nucleobases,  
 708 respectively. \* indicates the early termination mutation. Arrow sizes do not represent gene lengths.


1  
2  
3 709 Colors: blue, amino acid deletions, frame shift mutations, early termination mutations; green,  
4  
5 710 synonymous mutations; purple, single nucleotide mutations; orange, single amino acid changes.  
6  
7  
8 711 **(C)** Central carbon metabolism of KT2440 with the heterologous xylose and galactose utilization  
9  
10 712 genes. Red and blue arrows indicate the Weimberg and Leloir pathways, respectively.  
11  
12 713 Heterologous genes were colored in red or blue. Abbreviations: 2-KG, 2-ketogluconate; G6P,  
13  
14 714 glucose-6-phosphate (P); 6PG, 6-phosphogluconate; 2KG6P, 2-ketogluconate-6-P; Gal1P,  
15  
16 715 galactose-1-P; UDP-Glc, uridine diphosphate-glucose; UDP-Gal, uridine diphosphate galactose;  
17  
18 716 G1P, glucose-1-P; KDPG, 2-dehydro-3-deoxy-phosphogluconate; PYR, pyruvate; G3P,  
19  
20 717 glyceraldehyde-3-P; 3PG, glycerate-3-P; 2PG, 2-phosphoglycerate; PEP, phosphoenolpyruvate;  
21  
22 718 acetyl-CoA, acetyl coenzyme A (CoA), CIT, citrate; ICT, isocitrate;  $\alpha$ KG,  $\alpha$ -ketoglutarate; SUC-  
23  
24 719 CoA, succinyl-CoA; SUC, succinate; FUM, fumarate; MAL, malate; OAA, oxaloacetate; GLY,  
25  
26 720 glyoxylate. Genes in bold are involved in xylose or galactose utilization or close to mutated genes.  
27  
28  
29  
30  
31 721 **(D)** Log<sub>2</sub> Transcripts Per Million (TPM) fold changes of genes related to sugar catabolism. Actual  
32  
33 722 values were provided in Supplementary Data 3.  
34  
35

36  
37 723  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

724 **Figure 4. Validation of xylose and galactose metabolism in evolved strains**

725  
726 **(A and B)** Growth profiles of the **(A)** A1\_F11\_I1 (black circle), A1\_F11\_I1\_Δ*xylD* (red square),  
727 and A1\_F11\_I1\_Δ*kguT* (green down triangle) strains in the xylose minimal medium and **(B)**  
728 A6\_F90\_I1 (black circle), A6\_F90\_I1\_Δ*galETKM* (red square), and A6\_F90\_I1\_Δ*gtsABCD*  
729 (green down triangle) strains in the galactose minimal medium. These strains were cultivated using  
730 a microtiter plate reader. Growth **(C)** and sugar consumption profiles **(D)** of A5\_F85\_I1 (black  
731 open circle), A5\_F85\_I1\_Δ*gcd* (black closed circle), A8\_F92\_I1 (red open square),  
732 A8\_F92\_I1\_Δ*gcd* (red closed square) strains. **(A-D)** *x*-axis indicates time (h). *y*-axis indicates **(A-**  
733 **C)** OD<sub>600</sub> or **(D)** galactose concentration (g/L). The cultures were conducted with three biological  
734 replicates (*n*=3) and error bars indicate the standard deviations.

735 **Figure 5. Indigoidine production from xylose and galactose by using evolved strains as hosts**



(A) The indigoidine production pathway engineered into *P. putida* strains. Indigoidine can be produced by heterologous expression of *bpsA* from *S. lavendulae* and *sfp* from *B. subtilis* for conversion of glutamine. These genes were expressed under the arabinose inducible promoter ( $P_{ara}$ ). (B) Comparison of the indigoidine titers (g/L) of the initial engineered strains (not detected, n.d.), evolved isolates, and two evolved isolates with a *gcd* deletion after 24 h (light blue) and 48 h (dark blue) cultivation. The *bpsA* and *sgfp* expression cassette was integrated into the chromosome of each host strain. Four biological replicates ( $n=4$ ) were performed, and error bars indicate the standard deviations.